Earnings Feed
Start Free
Corvus Pharmaceuticals, Inc.·4

Jan 30, 6:39 PM ET

Thompson Peter A. 4

Research Summary

AI-generated summary

Updated

Corvus (CRVS) 10% Owner Peter A. Thompson Exercises Options (~$1.12M)

What Happened
Peter A. Thompson (identified as a 10% owner) exercised multiple stock option tranches on January 28, 2026, resulting in the acquisition of 210,000 common shares of Corvus Pharmaceuticals (CRVS). The exercises involved a range of strike prices (from $0.96 up to $15.00) and required aggregate cash payment of approximately $1.12 million. Corresponding derivative interests (the options) were recorded as disposed at $0 consideration (i.e., the options were converted into shares).

Key Details

  • Transaction date: January 28, 2026 (Form 4 filed Jan 30, 2026).
  • Shares acquired: 210,000 common shares (sum of one 30,000 tranche and twelve 15,000 tranches).
  • Cash paid (aggregate): ~$1,119,374 (reported exercise prices include $15.00, $9.70, $12.50, $3.61, $2.00, $3.27, $2.74, $2.60, $0.99, $0.96, $2.49, $1.64, $2.12).
  • Dispositions: 210,000 derivative securities shown disposed at $0.00 (reflecting conversion of options into shares). Transaction code: M = option exercise/conversion.
  • Shares owned after transaction: not specified in the provided excerpt.
  • Footnotes of note: F1–F3 indicate Thompson is obligated to transfer the securities or economic benefits to OrbiMed Advisors LLC / OrbiMed Capital GP V LLC for delivery to OrbiMed Private Investments V, LP (OPI V), and disclaims beneficial ownership except for any pecuniary interest. F2 notes Thompson is a member of OrbiMed Advisors. This means the activity relates to OrbiMed’s institutional position rather than a conventional executive cash buy/sell.
  • Filing timeliness: No late-filing flag indicated (filed Jan 30 for Jan 28 transactions).

Context

  • M-code (option exercise): Thompson exercised vested options and received underlying common shares; the options were extinguished (reported as disposed at $0). This was an exercise, not an open-market purchase or sale of shares.
  • Institutional note: Because of transfer/assignment provisions and the Form 4 footnotes, these actions appear tied to OrbiMed’s management/holding structure (institutional), not necessarily an individual personal investment decision.